Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma

Journal of Veterinary Medical Science

Volumn 72, Issue 9, 2010, Pages 1165-1172

  Tomiyasu, Hirotaka ^a   Goto Koshino, Yuko ^a   Takahashi, Masashi ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Canine; Drug resistance; Lymphoma; Real time RT PCR; Sequence analysis

Indexed keywords

CANIS FAMILIARIS;

EID: 77958484000     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.09-0575     Document Type: Article

References (36)

1. Bergman, P. J. 2003. Mechanisms of anticancer drug resistance. Vet. Clin. North. Am. Small Anim. Pract. 33: 651-657.
2. Bergman, P. J., Ogilvie, G. K. and Powers, B. E. 1996. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J. Vet. Intern. Med. 10: 354-359.
3. Brent, T. P., Houghton, P. J. and Houghton, J. A. 1985. O6- Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)- 1-nitrosourea. Proc. Natl. Acad. Sci. U. S. A. 82: 2985-2989.
4. Buchholz, T. A., Davis, D. W., McConkey, D. J., Symmans, W. F., Valero, V., Jhingran, A., Tucker, S. L., Pusztai, L., Cristofanilli, M., Esteva, F. J., Hortobagyi, G. N. and Sahin, A. A. 2003. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 9: 33-41.
5. Burger, H., Foekens, J. A., Look, M. P., Meijer-van Gelder, M. E., Klijn, J. G., Wiemer, E. A., Stoter, G. and Nooter, K. 2003. RNA expression of breast cancer resistance protein, lung resistance- related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9: 827-836.
6. Burnett, R. C., Vernau, W., Modiano, J. F., Olver, C. S., Moore, P. F. and Avery, A. C. 2003. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet. Pathol. 40: 32-41.
7. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45: 228-247.
8. Fournel-Fleury, C., Magnol, J. P., Bricaire, P., Marchal, T., Chabanne, L., Delverdier, A., Bryon, P. A. and Felman, P. 1997. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non- Hodgkin's lymphomas. J. Comp. Pathol. 117: 35-59.
9. Garrett, L. D., Thamm, D. H., Chun, R., Dudley, R. and Vail, D. M. 2002. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 16: 704-709.
10. Gerson, S. L. 2004. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4: 296-307.
11. Gimenez-Bonafe, P., Tortosa, A. and Perez-Tomas, R. 2009. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targets 9: 320-340.
12. Harris, A. L. and Hochhauser, D. 1992. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 31: 205-213.
13. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A. and Brenner, M. K. 2004. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 101: 14228-14233.
14. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Shoemaker, R. H., Rome, L. H. and Scheper, R. J. 1996. Relationship of LRPhuman major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19: 191-197.
15. Kaina, B. and Christmann, M. 2002. DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharmacol. Ther. 40: 354-367.
16. Khor, L. Y., Moughan, J., Al-Saleem, T., Hammond, E. H., Venkatesan, V., Rosenthal, S. A., Ritter, M. A., Sandler, H. M., Hanks, G. E., Shipley, W. U. and Pollack, A. 2007. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin. Cancer Res. 13: 3585-3590.
17. Kim, E., Giese, A. and Deppert, W. 2009. Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem. Pharmacol. 77: 11-20.
18. Kourti, M., Vavatsi, N., Gombakis, N., Sidi V., Tzimagiorgis, G., Papageorgiou, T., Koliouskas, D. and Athanassiadou, F. 2007. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int. J. Hematol. 86: 166-173.
19. Kupryjanczyk, J., Szymanska, T., Madry, R., Timorek, A., Stelmachow, J., Karpinska, G., Rembiszewska, A., Ziolkowska, I., Kraszewska, E., Debniak, J., Emerich, J., Ulanska, M., Pluzanska, A., Jedryka, M., Goluda, M., Chudecka- Glaz, A., Rzepka-Gorska, I., Klimek, M., Urbanski, K., Breborowicz, J., Zielinski, J. and Markowska, J. 2003. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinumbased regimen. Br. J. Cancer 88: 848-854.
20. Lage, H. 2008. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life. Sci. 65: 3145-3167.
21. Lee, J. J., Hughes, C. S., Fine, R. L. and Page, R. L. 1996. Pglycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 77: 1892-1898.
22. Lee, T. B., Park, J. H., Min, Y. D., Kim, K. J. and Choi, C. H. 2008. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC. Gastroenterol. 8: 33.
23. Luqmani, Y. A. 2005. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 14 (Suppl 1): 35-48.
24. MacDonald, V. S., Thamm, D. H., Kurzman, I. D., Turek, M. M. and Vail, D. M. 2005. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J. Vet. Intern. Med. 19: 732-736.
25. Moore, A. S., Leveille, C. R., Reimann, K. A., Shu, H. and Arias, I. M. 1995. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest. 13: 475-479.
26. Moscow, J. A. and Dixon, K. H. 1993. Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 12: 155-170.
27. Nagamatsu, K., Tsuchiya, F., Oguma, K., Maruyama, H., Kano, R. and Hasegawa, A. 2008. The effect of small interfering RNA (siRNA) against the Bcl-2 gene on apoptosis and chemosensitivity in a canine mammary gland tumor cell line. Res. Vet. Sci. 84: 49-55.
28. O'Connor, R. 2007. The pharmacology of cancer resistance. Anticancer Res. 27: 1267-1272.
29. Peters, I. R., Peeters, D., Helps, C. R. and Day, M. J. 2007. Development and application of multiple internal reference (housekeeper) gene assays for accurate normalisation of canine gene expression studies. Vet. Immunol. Immunopathol. 117: 55-66.
30. Schlotter, Y. M., Veenhof, E. Z., Brinkhof, B., Rutten, V. P., Spee, B., Willemse, T. and Penning, L. C. 2009. A GeNorm algorithm-based selection of reference genes for quantitative real-time PCR in skin biopsies of healthy dogs and dogs with atopic dermatitis. Vet. Immunol. Immunopathol. 129: 115-118.
31. Schold, S. C., Jr., Brent, T. P., von Hofe, E., Friedman, H. S., Mitra, S., Bigner, D. D., Swenberg, J. A. and Kleihues, P. 1989. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J. Neurosurg. 70: 573-577.
32. Setoguchi, A., Sakai, T., Okuda, M., Minehata, K., Yazawa, M., Ishizaka T., Watari, T., Nishimura, R., Sasaki, N., Hasegawa, A. and Tsujimoto, H. 2001. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am. J. Vet. Res. 62: 433-439.
33. Steingold, S. F., Sharp, N. J., McGahan, M. C., Hughes, C. S., Dunn, S. E. and Page, R. L. 1998. Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer. Res. 18: 393-400.
34. Uozurmi, K., Nakaichi, M., Yamamoto, Y., Une, S. and Taura, Y. 2005. Development of multidrug resistance in a canine lymphoma cell line. Res. Vet. Sci. 78: 217-224.
35. Voorzanger-Rousselot, N. and Blay, J. Y. 2004. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk. Lymphoma. 45: 1239-1245.
36. Voorzanger-Rousselot, N., Favrot, M. and Blay, J. Y. 1998. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 92: 3381-3387.